Infectious Disease · Medical Literature
[News] WHO's new influenza vaccine recommendations
Abstract
On Feb 27, 2026, WHO released its recommendations for the composition of the influenza vaccines for the 2026–27 season in the northern hemisphere. These recommendations are issued twice a year, once for each hemisphere, after a consultation process that centres on an analysis of global influenza surveillance data. For the forthcoming northern hemisphere influenza season, WHO has recommended vaccines targeting A(H1N1), A(H3N2), and B/Victoria lineage.
Clinical relevance
What are WHO's recommended influenza vaccine strain compositions for the 2026–27 northern hemisphere season, and what epidemiological and virological rationale underpins these selections? __SNAPSHOT__ {"studyDesign":"News report / policy communication piece summarizing WHO vaccine strain selection recommendations; not an original research study or clinical trial","setting":"Global; WHO Global Influenza Surveillance and Response System (GISRS), with data aggregated from national surveillance networks worldwide","sampleSize":"Not applicable — this is a policy summary, not a clinical study with an enrolled patient population","population":"Populations globally eligible for seasonal influenza vaccination in the northern hemisphere; no specific patient inclusion/exclusion criteria defined","intervention":"Trivalent seasonal influenza vaccine formulated according to WHO's 2026–27 northern hemisphere recommendations, targeting A(H1N1)pdm09, A(H3N2), and B/Victoria lineage strains","comparator":"Not applicable — this is a recommendation statement, not a comparative clinical trial","primaryOutcome":"Specification of recommended vaccine strain composition for the 2026–27 northern hemisphere influenza season; no clinical efficacy or effectiveness endpoint assessed","followUp":"Not applicable","fundingSource":"World Health Organization (intergovernmental/non-profit); Lancet Microbe published the accompanying news piece"}
Key findings
On February 27, 2026, following a 4-day expert consultation analyzing global influenza surveillance data, WHO recommended updates to all three components of the northern hemisphere trivalent influenza vaccine for 2026–27. For egg-based vaccines: A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1454/2025 (H3N2)-like, and B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like viruses. For cell culture-, recombinant protein-, or nucleic acid-based vaccines: A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1415/2025 (H3N2)-like, and B/Pennsylvania/14/2025 (B/Victoria lineage)-like viruses. A key epidemiological driver was the emergence in August 2025 of a notably different A(H3N2) variant (classified as J.2.4.1, also referred to as 'subclade K'), which spread rapidly globally and contributed to an earlier influenza season start and higher-than-usual activity levels in several countries. Pre-consultation serology data suggested that most individuals had low neutralizing antibody titers against the emergent H3N2 subclade K and H1N1 D.3.1.1 viruses, underscoring the urgency of the H3N2 and H1N1 strain updates. All three vaccine components were updated from the prior season. No vaccine efficacy or effectiveness estimates, confidence intervals, p-values, NNT, or NNH are reported, as this is a strain selection recommendation document, not an efficacy trial.
Practice implications
This WHO recommendation establishes the antigenic targets for 2026–27 northern hemisphere influenza vaccines and is directly actionable for clinicians, public health authorities, and pharmacists ordering or administering influenza vaccines. All three strains have been updated relative to 2025–26, reflecting significant antigenic drift—particularly in A(H3N2) (subclade K emergence) and A(H1N1). The recommendation does not establish vaccine efficacy or effectiveness against these strains; those data will only become available after the upcoming season. Clinicians should note that the 2026 Southern Hemisphere vaccine formulation retains older H3N2 and B strains and may therefore be less optimally matched if used in the northern hemisphere context. The WHO advisory committee has reiterated that B/Yamagata lineage antigen inclusion is no longer warranted given the continued absence of confirmed circulating B/Yamagata viruses since March 2020, supporting the continued shift to trivalent formulations. Zoonotic influenza surveillance during the preceding period identified 25 human infections from 6 countries, none involving human-to-human transmission; experts recommended development of a new candidate vaccine virus for A(H9N2) for pandemic preparedness purposes. Because only the abstract of the Lancet Microbe news piece was provided, additional contextual detail from the full article may not be captured here. __LIMITATIONS__ 1. Article type: This is a news/policy communication, not a clinical trial or systematic review; no efficacy, effectiveness, immunogenicity, or safety data are reported. 2. Strain selection lead time: Vaccine composition decisions must be made approximately six months in advance of the season, creating an inherent window for further antigenic drift that could reduce vaccine-strain match. 3. No effectiveness estimates: Real-world vaccine effectiveness against the recommended 2026–27 strains is unknown at the time of this publication. 4. Manufacture-specific antigenic differences: Egg-adapted and cell/recombinant vaccine strain designations differ (e.g., Darwin/1454 vs. Darwin/1415 for H3N2), reflecting known egg-adaptation artifacts that may affect antigenic fidelity—particularly relevant for H3N2. 5. Population-level uptake not addressed: Declining influenza vaccine uptake trends, particularly in the United States, are noted contextually but not studied here. 6. Only the abstract of the Lancet Microbe piece was available for review; the full article may contain additional virological detail, epidemiological data, or expert commentary not captured in this summary. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ WHO has updated all three components of the 2026–27 northern hemisphere trivalent influenza vaccine, driven primarily by rapid global spread of an antigenically distinct A(H3N2) subclade K variant and evidence of reduced population immunity to both H3N2 and H1N1 circulating strains. Clinicians should ensure patients receive the updated 2026–27 northern hemisphere formulation and not substitute the 2026 southern hemisphere formulation, which retains older H3N2 and B strains. Vaccine effectiveness data against these updated strains will not be available until mid-to-late season.